Tag : Biosimilar

Pharma / Biotech

A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers.

Newsemia
Related Articles A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers. Expert Opin Investig...
Latest News

Meiji Seika Pharma and Dong-A Socio Holdings Initiate Phase I Clinical Trial of DMB-3115, a Ustekinumab Biosimilar Candidate

Newsemia
TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, “Meiji”) and Dong-A Socio Holdings Co., Ltd. (Headquarters: Seoul, Korea,...
Latest News

Biosimilar for HER2+ breast cancer achieves similar overall response rate to reference drug

Newsemia
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously...
Latest News

Nuevos datos demuestran la no-inferioridad en la eficacia de la fórmula subcutánea de CT-P13 (biosimilar de infliximab) respecto a la fórmula intravenosa de CT-P13 en personas con artritis reumatoide

Newsemia
ATLANTA–(BUSINESS WIRE)–Celltrion Healthcare ha anunciado hoy en el Congreso Anual del American College of Rheumatology (ACR), los datos de un estudio que investiga en mayor...
Pharma / Biotech

Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.

Newsemia
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. Inflamm Bowel Dis. 2019 Oct...
Latest News

Neue subkutane Formulierung von CT-P13 von Celltrion Healthcare (Biosimilar Infliximab) zeigt positive Phase-I-Ergebnisse für die Behandlung von chronisch-entzündlichen Darmerkrankungen (IBD) mit Daten…

Newsemia
BARCELONA, Spanien–(BUSINESS WIRE)–  Neue subkutane Formulierung von CT-P13 von Celltrion Healthcare (Biosimilar Infliximab) zeigt positive Phase-I-Ergebnisse für die Behandlung von chronisch-entzündlichen Darmerkrankungen (IBD) mit Daten,...
Latest News

Nueva fórmula subcutánea de CT-P13 (biosimilar de infliximab) de Celltrion Healthcare muestra resultados positivos para el tratamiento de la IBD (Enfermedad Intestinal Inflamatoria) en la Semana Europea de Gastroenterología en Barcelona 2019

Newsemia
BARCELONA, España–(BUSINESS WIRE)–Celltrion Healthcare presentó hoy nuevos datos de un estudio de Fase 1 central para evaluar la farmacocinética (PK), la eficacia y la seguridad...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy